PubMed

Machine Learning-Enabled Medical Devices Authorized by the US Food and Drug Administration in 2024: Regulatory Characteristics, Predicate Lineage, and Transparency Reporting.

PMID: 41463017 · 2025-12-08

B, a, s, s, e, l, , A, l, m, a, r, i, e, ;, , L, u, i, s, , F, e, r, n, a, n, d, o, , G, o, n, z, a, l, e, z, -, G, o, n, z, a, l, e, z, ;, , L, u, c, a, s, , A, n, t, ô, n, i, o, , D, o, s, , S, a, n, t, o, s, , B, a, r, b, o, s, a, ;, , A, m, e, l, i, e, , L, u, t, z, ;, , U, l, r, i, c, h, , G, r, o, s, s, e, ;, , F, e, l, i, p, e, , F, r, e, g, n, i

학술지Biomedicines

연도2025-12-08

PMID41463017

초록

Background: The US Food and Drug Administration (FDA) authorized over 690 machine learning (ML)-enabled medical devices between 1995 and 2023. In 2024, new guidance enabled the inclusion of Predetermined Change Control Plans (PCCPs), raising expectations for transparency, equity, and safety under the Good Machine Learning Practice (GMLP) framework. Objective: The objective was to assess regulatory pathways, predicate lineage, demographic transparency, performance reporting, and PCCP uptake among

공식 출처

PubMed에서 보기 →

데이터는 PubMed / NCBI에서 제공됩니다. 전문과 최신 정보는 반드시 공식 기록을 확인하세요.